Perspectives from those who live it every day.
--This post was written by freelance writer Becky Ham. A compound made from the tree’s bark shows promise against tumors spurred by the leptin hormone.… Read More »Can Magnolia Help Break the Link Between Obesity and Breast Cancer?
Julie Brahmer, M.D., director of the Thoracic Oncology Program, began treating patients with immunotherapy drugs nearly a decade ago. She led one of the first… Read More »Side effects of immunotherapy: what to look for and when?
Tom Smith, M.D., wants cancer patients to live well. Fewer side effects, better quality of life, more joyful time with family…these are among the primary… Read More »Palliative medicine focus at #ASCO16 meeting
Immunotherapy expert, Suzanne Topalian, M.D., delivered a presentation to a standing room only crowd at the 2016 American Society of Clinical Oncology (#ASCO16) regarding new… Read More »Can biomarkers predict patients’ response to immunotherapy?
With recent FDA approvals of immunotherapy drugs for kidney and bladder cancer, patients now have more options to consider among their treatments. The 2016 ASCO… Read More »ASCO annual meeting features clinical trial results of immunotherapy for bladder and kidney cancer
A new immunotherapy drug -- the first in its class -- was approved by the Food and Drug Administration last week for bladder cancer. We… Read More »New immunotherapy drug approved to treat bladder cancer
This past weekend, the Avon Foundation held its 14th annual event in Washington, D.C. to raise funds for breast cancer research and education. More than 1,900… Read More »Avon awards Kimmel Cancer Center more than $1 million for breast cancer research and support
In today's lineup of stories covered by WNYC's radio program The Takeaway, Kimmel Cancer Center expert Josh Lauring, M.D., Ph.D., provides his perspective on a new study… Read More »Perspective on a breast cancer genome sequencing study
At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma… Read More »One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years
***Note: This is the final post of a four-part feature story, written by Elizabeth Huebeck. Read part one on Kristin's story, part two on cancer as… Read More »Pay close attention to your overall health